Nuchal translucency screening and antenatal maternal serum screening for Down syndrome: results of a project

Distribution of nuchal translucency in antenatal screening for Down's syndrome

OBJECTIVE To determine whether the standard deviation of nuchal translucency (NT) measurements has decreased over time and if so to revise the estimate and assess the effect of revising the estimate of the standard deviation on the performance of antenatal screening for Down's syndrome. SETTING Data from a routine antenatal screening programme for Down's syndrome comprising 106 affected and 2...

Nuchal translucency measurement in first trimester Down syndrome screening.

(1) Approximately three in every four fetuses with Down syndrome have increased nuchal translucency (NT), which is a larger than normal build-up of fluid at the back of the neck. (2) The ultrasound measurement of NT between 11 and 14 weeks' gestation, in combination with the mother's age and the levels of placental biochemical markers in her blood, can be used to detect approximately 84% of fet...

Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.

OBJECTIVES To assess the implementation of antenatal screening for Down's syndrome in practice, using individual risk estimates based on maternal age and the three serum markers: alpha fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin. DESIGN Demonstration project of Down's syndrome screening; women with a risk estimate at term of 1 in 250 or greater were classified as "sc...

Nuchal translucency and first trimester biochemical markers for Down syndrome screening: a cost-effectiveness analysis

Nuchal translucency and first trimester biochemical markers for Down syndrome screening: a cost-effectiveness analysis